Evidence map›Paper›PMID 35139856›Full record

Observational studyRadiation oncology (London, England)2022

PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study.

Matthias Mäurer, Lukas Käsmann, Daniel F Fleischmann, Michael Oertel, Danny Jazmati, Daniel Medenwald, Young DEGRO Trial Group

Registry-linked trialOpen access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03055715 (Multicentric Retrospective Prognostic Evaluation of Tumor Volume and Their Change in the Curative-intended, Radical Radiotherapy of Locally Advanced NSCLC), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03055715 completednot on this map

Multicentric Retrospective Prognostic Evaluation of Tumor Volume and Their Change in the Curative-intended, Radical Radiotherapy of Locally Advanced NSCLC

TypeobservationalSponsorMartin-Luther-Universität Halle-WittenbergRan2017 to 2018Enrolled346ConditionsNon Small Cell Lung Cancer Stage III
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Tenth anniversary of the Young DEGRO Team Trial-reflecting on the past, shaping the future.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Article
  2. Observational
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Matthias MäurerDepartment of Radiation Oncology, University Medical Center Jena, Jena, Germany. matthias.maeurer@med.uni-jena.de.ORCID http://orcid.org/0000-0001-9662-3082
Lukas KäsmannDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Daniel F FleischmannDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.
Michael OertelDepartment of Radiation Oncology, University Medical Center Muenster, Muenster, Germany.
Danny JazmatiDepartment of Particle Therapy, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), University Hospital Essen, Essen, Germany.
Daniel MedenwaldDepartment of Radiation Oncology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Young DEGRO Trial Group
LMU Klinikum · DEJena University Hospital · DEMartin Luther University Halle-Wittenberg · DEWest German Heart and Vascular Center Essen · DE

Funding

Deutsche Forschungsgemeinschaft WI 830/12-1
6 · The paper itself

Abstract

backgroundStage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC. METHOD AND PATIENTS: A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side.

resultsPatients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89-1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56-1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41-0.94).

conclusionA consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning.

Indexed as

Positron Emission Tomography Computed TomographyRadiotherapy, Image-GuidedAgedCarcinoma, Non-Small-Cell LungCohort StudiesFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesSurvival RateAdaptive radiotherapyLung cancerNon small cell lung cancerPET/CT

Identifiers

PMID35139856
PMCPMC8827193
OpenAlexW4210857984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.